Pyrotinib

Pyrotinib

• CAS Number: 1269662-73-8
• UNSPSC Description: Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively[1].
• Target Antigen: EGFR
• Type: Reference compound
• Related Pathways: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Pyrotinib.html
• Purity: 99.89
• Solubility: 0.1 M Maleic Acid : 16.67 mg/mL (ultrasonic)|1 M Maleic Acid : 100 mg/mL (ultrasonic)|DMSO : 10 mg/mL (ultrasonic;adjust pH to 6 with HCl)
• Smiles: O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5
• Molecular Weight: 583.08
• References & Citations: [1]Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X.Biomed Pharmacother. 2024 Oct 14:180:117523.|Biosci Rep. 2020 Feb 28;40(2):BSR20194167.|Cell Rep Med. 2023 Jan 10;100911.|Clin Transl Oncol. 2024 May 25.|Int J Biol Macromol. 2023 May 19;242(Pt 2):124870.|iScience. 2024 Jan 9;27(2):108839.|J Med Chem. 2019 May 9;62(9):4772-4778.|J Thorac Oncol. 2023 Sep 5;S1556-0864(23)00802-X.|Lung Cancer. 2018 Dec;126:72-79.|Mol Syst Biol. 2023 Dec 18.|Patent. US 20220175778A1.|Patent. US20210361655A1.|STAR Protoc. 2024 Apr 16;5(2):102987.|Int J Cancer. 2024 Jul 15;155(2):324-338.|Open Life Sci. 2023, 18(1).
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched